Frankfurt Am Main

• A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection Ended recruitment
  2025-521096-31-00 5 2025-10-02 Chronic Hepatitis C Virus (HCV) Infection
• Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended recruitment
  2025-521681-10-00 4 2025-10-02 Lung Cancer
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria Ended recruitment
  2024-520031-33-00 4 2025-09-16 Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
• Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) Ended recruitment
  2024-511452-40-00 10 2025-09-12 Oncology - Glioblastoma (GBM)
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• A clinical study of tulisokibart in people with hidradenitis suppurativa (MK-7240-012) Ended recruitment
  2024-520039-33-00 10 2025-08-11 Hidradenitis Suppurativa
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Ended recruitment
  2024-515919-22-00 5 2025-06-02 Chronic Hepatitis D Virus (HDV) Infection
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors. Ended recruitment
  2024-516733-12-00 1 2025-05-13 Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorect
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease Ended recruitment
  2023-506880-32-01 1 2025-04-14 Pulmonary Disease, Chronic Obstructive
• A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Ended recruitment
  2024-515741-42-00 5 2025-03-28 hereditary angioedema due to C1 esterase inhibitor deficiency (Type 1
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• An Open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets Ended recruitment
  2024-514292-18-00 5 2025-03-24 Primary Sclerosing Cholangitis (PSC)

Showing 457–480 of 912 trials